eFFECTOR shelves tomivosertib in NSCLC following Phase II failure - Clinical Trials Arena

Retrieved on: 2024-04-04 22:16:45

Tags for this article:

Orphan drugs

Antineoplastic drugs

Lung cancer

Cancer immunotherapy

Pembrolizumab

Non-small-cell lung cancer

Cemiplimab

Click the tags to see associated articles and topics

eFFECTOR shelves tomivosertib in NSCLC following Phase II failure - Clinical Trials Arena. View article details on HISWAI: https://www.clinicaltrialsarena.com/news/effector-shelves-tomivosertib-in-nsclc-following-phase-ii-failure/

Summary

The article discusses eFFECTOR Therapeutics halting the development of tomivosertib for NSCLC due to its Phase II trial not meeting endpoints. Business intelligence in pharma could analyze such trial outcomes and market dynamics.

Article found on: www.clinicaltrialsarena.com

View Original Article